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Perspective
W
hether decisions about the 
health care of children are 
made by parents, carers, 
health practitioners, or children 
themselves, ideally these decisions 
will be informed by the results of 
systematic reviews of previous clinical 
trials. Unfortunately, drawing on 
research from the past when making 
these decisions is not straightforward, 
even with the advent of systematic 
reviews, because different trials have 
used different outcome measures. 
Indeed, systematic reviews have helped 
to highlight the problems that arise 
when researchers from different times 
and places—sometimes even in the 
same times and places—use a variety 
of health outcomes and outcome 
measures to assess the effect of 
interventions [1]. 
In a new systematic review published 
in this issue of PLoS Medicine, Ian Sinha 
and colleagues examined studies that 
involved the selection of outcomes for 
use in paediatric clinical trials [2]. As 
they say in their report, the choice of 
outcome is important because choosing 
inappropriate outcomes may lead 
to “wasted resources or misleading 
information which either overestimates, 
underestimates or completely 
misses the potential beneﬁts of an 
intervention.”
Setting the Scene
In trying to decide whether the work 
done by Sinha and colleagues is 
important, a useful starting point is 
knowing just how many clinical trials 
have been conducted in children. 
Although it is difﬁcult to ﬁnd a reliable 
ﬁgure, a search of the Cochrane 
Central Register of Controlled Trials, 
the world’s single largest repository 
of records for randomised trials, ﬁnds 
more than 30,000 reports simply on 
the basis of having the words “child” 
or “children” in either their title or 
abstract. A PubMed search, limiting the 
records to all reports about humans, 
ﬁnds a total of just over 10 million 
articles. Further limiting this search 
to records for “clinical trials” brings 
this ﬁgure down to about 520,000, and 
limiting this again to “children” found 
127,904 (search performed March 17, 
2008). If you try again now, one month 
later, you’ll get a sense of how fast 
things are moving—even in one month 
it is likely that additional child health 
trials have been published. Moreover, 
anyone trying to compare and contrast 
different paediatric trials will be faced 
by a wide variety of outcomes reported 
and a wide variety of ways in which the 
same outcomes were measured.
Trial Outcome Measures for 
Children
Sinha and colleagues set out to ﬁnd 
reports of studies done to determine 
or agree upon a standard set of 
outcome measures for clinical trials 
involving children. Doing a systematic 
review helped them to minimise bias 
in making decisions about how to 
search the literature, what to include 
and exclude, and how to report their 
ﬁndings. Their initial wide search 
retrieved nearly 9,000 abstracts, which 
led to 70 articles being evaluated in 
full, leading ultimately to 25 eligible 
articles from 13 collaborative groups. 
(Figure 2 in [2] shows the ﬂow of 
papers through the systematic review 
process.) 
Perhaps the most consistent, and 
alarming, ﬁnding across the 25 studies 
was that none of them involved 
children in the process of determining 
the selection of outcomes, although the 
authors note the potential challenges 
of doing so. There were 13 paediatric 
conditions, including asthma, Crohn’s 
disease, and cystic ﬁbrosis, as well as a 
number of clinical symptoms or signs, 
such as pain and apnoea, for which 
research has been done to determine 
which outcomes should be measured 
in trials. 
Implications of the New Study
Reaching agreement on standard 
outcomes for clinical trials in children 
is important to enable researchers 
and clinicians to compare, contrast, 
and combine the ﬁndings of these 
trials. Such agreement should also 
help to reduce the possibility of biased 
reporting. If researchers have a choice 
of outcomes, they might be tempted to 
report selectively, emphasising those 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS 
Medicine:
Sinha I, Jones L, Smyth RL, Williamson 
PR (2008) A systematic review of studies 
that aim to determine which outcomes 
to measure in clinical trials in children. 
PLoS Med 5(4): e96. doi:10.1371/journal.
pmed.0050096
Ian Sinha and colleagues show, 
in a systematic review of published 
studies, that there are very few studies 
that address the appropriate choice 
of outcomes for clinical research with 
children.PLoS Medicine  |  www.plosmedicine.org 0522 April 2008  |  Volume 5  |  Issue 4  |  e102
that give them the results they ﬁnd 
most attractive and/or omitting those 
that are unfavourable to their point of 
view [3]. When there is a standard set 
of outcomes and outcome measures, 
users of the results of trials should be 
rightly cautious of any trials that do not 
report all of these outcomes.
Next Steps
Sinha and colleagues identiﬁed 13 
groups who have tried to tackle the 
problem of poor standardisation 
in the outcomes of clinical trials in 
children. These groups are not alone 
among those seeking to standardise 
trial outcomes. In the early 1990s, the 
Outcome Measures in Rheumatology 
Group (OMERACT; see http://www.
omeract.org/) began its efforts to 
produce standardisation in assessments 
of the effects of treatments for 
rheumatoid arthritis [4], and a similar 
process was reported recently for 
ulcerative colitis [5]. The success of 
OMERACT probably owes much to its 
attempts to reach a consensus among 
major stakeholders. Recommendations 
for chronic pain research, developed 
by a group called the Initiative 
on Methods, Measurement, and 
Pain Assessment in Clinical Trials 
(IMMPACT; http://www.immpact.
org/), followed the OMERACT model 
[6]. An electronic Delphi survey, as 
used by several of the groups working 
in child health, was also used to 
prepare a core set of outcomes for 
maternity care [7].
Making trials from the past and 
present more useful to decision makers 
in child health in the future will require 
uptake of the recommendations 
proposed in studies such as those 
found by Sinha and colleagues. But the 
challenges of achieving standardised 
outcomes in clinical trials are 
formidable. These challenges are well 
demonstrated in research in adults 
with schizophrenia. In the 1990s, 2,000 
trials of schizophrenia were found to 
have used 640 different rating scales in 
their assessments of 600 interventions 
[8]. A subsequent systematic review 
of chlorpromazine versus placebo for 
schizophrenia noted: “If rating scales 
are to be employed, a concerted effort 
should be made to agree on which 
measures are the most useful. Studies 
within this review reported on so many 
scales that, even if results had not been 
poorly reported, they would have been 
difﬁcult to synthesise in a clinically 
meaningful way” [9]. A similar lack of 
standardisation in trial outcomes has 
been noted for research on asthma and 
the common cold. In their Cochrane 
systematic review of inhaled magnesium 
sulphate for asthma, Blitz and 
colleagues wrote that “There is a strong 
argument for asthma researchers to 
develop a consensus regarding the 
reporting of pulmonary function 
results” [10]. Similarly, in their 
systematic review of echinacea for the 
common cold, Linde and colleagues 
noted that “It would be desirable if 
experts in research on common colds 
would develop recommendations for 
a core set of outcome measures to 
be used and reported in randomized 
clinical trials” [11].
Conclusion
Sinha and colleagues have 
produced what is probably the most 
comprehensive account to date of 
efforts to standardise outcomes in 
clinical trials in children. As the 
authors say, referring to the studies 
they found, “When designing clinical 
trials in these conditions, this work 
should make the selection of outcomes 
easier and more uniform.” I would add 
that when trying to choose outcomes 
for clinical trials in any condition, 
Sinha and colleagues’ work should 
make it easier to plan, ﬁnd, appraise, 
and use initiatives that have already 
attempted to standardise these 
outcomes.  
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